Cita APA (7a ed.)

Alors-Perez, E., Blázquez-Encinas, R., Alcalá, S., Viyuela-García, C., Pedraza-Arevalo, S., Herrero-Aguayo, V., . . . Castaño, J. P. (2021). Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug. BMC.

Cita Chicago Style (17a ed.)

Alors-Perez, Emilia, et al. Dysregulated Splicing Factor SF3B1 Unveils a Dual Therapeutic Vulnerability to Target Pancreatic Cancer Cells and Cancer Stem Cells with an Anti-splicing Drug. BMC, 2021.

Cita MLA (8a ed.)

Alors-Perez, Emilia, et al. Dysregulated Splicing Factor SF3B1 Unveils a Dual Therapeutic Vulnerability to Target Pancreatic Cancer Cells and Cancer Stem Cells with an Anti-splicing Drug. BMC, 2021.